GlaxoSmithKline agreed to pay nearly $41 million to settle charges brought by 38 state attorneys general that the company tried to sell drugs made in a Puerto Rican plant that failed to meet manufacturing standards. The attorneys general alleged that, between 2001 and 2004, GlaxoSmithKline and its SB Pharmco Puerto Rico subsidiary engaged in unfair and deceptive practices when they manufactured and distributed certain lots of Kytril, Bactroban, Paxil CR, and Avandamet, produced in a plant in Cidra, Puerto Rico. An investigation found certain batches were not sterilized or medication contained different dosages than indicated on the bottle. See related GlaxoSmithKline instance, “Puerto Rico Drug Manufacturing Facility Settlement.”